EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) A Research-Orient

EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ): A Research-Oriented Overview of a Next-Generation Fluorescent mRNA Probe for Golgi Apparatus Imaging

Introduction
The Golgi apparatus is a pivotal organelle in eukaryotic cells, responsible for protein modification, sorting, and trafficking. Understanding its structure and dynamics is crucial for elucidating cellular physiology and pathophysiology, particularly in neurodegenerative diseases, cancer, and metabolic disorders (Wei & Seemann, 2017, Trends Cell Biol). Fluorescent probes targeting the Golgi apparatus have become indispensable in cell biology, enabling real-time visualization and functional studies. The EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) represents an innovative tool in this domain. This product is a synthetic, in vitro-transcribed mRNA encoding a Golgi-targeted mTurquoise2 fluorescent protein, incorporating N1-methylpseudouridine (m1Ψ) modifications and a proprietary 5' cap structure (EZ Cap™) to enhance stability and translational efficiency.
The mechanism of action involves cellular uptake of the modified mRNA, translation by the host cell’s ribosomes, and subsequent localization of the mTurquoise2 fusion protein to the Golgi apparatus. The mTurquoise2 variant is a cyan fluorescent protein with superior photostability and quantum yield compared to earlier CFPs (Goedhart et al., 2012, Nat Commun). The m1Ψ modification is known to reduce innate immune activation and increase mRNA stability and translational output (Andries et al., 2015, Nucleic Acids Res). The EZ Cap™ structure further enhances cap-dependent translation, making this probe highly effective for live-cell imaging and functional studies. [Related: protease and phosphatase inhibitor cocktail]

Clinical Value and Applications
The clinical value of the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) lies in its ability to facilitate advanced cellular imaging, which is critical for both basic research and translational applications. Key applications include: [Related: cocktail protease inhibitor]
1. **Live-cell imaging of Golgi dynamics:** The probe enables high-resolution, real-time visualization of Golgi morphology and trafficking events, which is essential for studying cellular responses to drugs, stress, or genetic perturbations (Lippincott-Schwartz & Phair, 2010, Nat Rev Mol Cell Biol).
2. **Disease modeling:** Alterations in Golgi structure are implicated in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as in cancer metastasis. The probe allows researchers to monitor Golgi integrity in disease models and assess the impact of therapeutic interventions (Joshi et al., 2015, Cell Health Cytoskelet).
3. **Drug screening:** The probe can be used in high-content screening platforms to identify compounds that modulate Golgi function, trafficking, or morphology, accelerating drug discovery efforts in oncology, neurology, and infectious diseases.
4. **Gene editing and delivery studies:** The mRNA format is compatible with co-transfection protocols, enabling multiplexed studies with CRISPR/Cas9 or other gene-editing systems to assess the impact of genetic modifications on Golgi structure and function.
By providing a robust and non-immunogenic means of labeling the Golgi apparatus, this probe addresses critical limitations of DNA-based transfection and traditional fluorescent dyes, such as cytotoxicity, low transfection efficiency, and poor temporal control. [Related: 63-89-8]

Key Challenges and Pain Points Addressed
Traditional approaches for Golgi labeling, including DNA plasmid transfection or small-molecule dyes, face several limitations:
- **Low transfection efficiency in primary cells and stem cells:** DNA-based methods often fail in hard-to-transfect cell types, limiting their utility in primary cultures and clinical samples (Kim & Eberwine, 2010, Nat Rev Neurosci).
- **Cytotoxicity and cellular stress:** Overexpression from plasmids or the use of certain dyes can induce cytotoxicity, alter organelle morphology, or trigger stress responses, confounding experimental results (Liu et al., 2018, J Cell Sci).
- **Innate immune activation:** Unmodified mRNA can activate pattern recognition receptors, leading to translational shutdown and cell death (Karikó et al., 2005, Immunity).
- **Photobleaching and spectral overlap:** Earlier fluorescent proteins and dyes suffer from rapid photobleaching and suboptimal spectral properties, limiting their use in long-term imaging or multiplexed experiments.
The EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) addresses these pain points through several innovations:
- **m1Ψ modification:** Reduces innate immune activation and increases mRNA stability and translation.
- **EZ Cap™ structure:** Enhances cap-dependent translation and mRNA stability.
- **mTurquoise2 fluorophore:** Provides high brightness, photostability, and minimal spectral overlap, enabling multiplexed imaging.
- **mRNA delivery:** Allows efficient transfection in a wide range of cell types, including primary and stem cells, with rapid and transient expression.
These features collectively enable more reliable, reproducible, and physiologically relevant studies of Golgi dynamics and function.

Literature Review
A growing body of literature supports the scientific rationale and utility of mRNA-based fluorescent probes, m1Ψ modifications, and advanced fluorescent proteins for organelle imaging:
1. **m1Ψ-modified mRNA for enhanced expression and reduced immunogenicity:** Andries et al. (2015, Nucleic Acids Res) demonstrated that m1Ψ incorporation into synthetic mRNA significantly reduces innate immune activation and increases protein expression in mammalian cells, supporting the use of such modifications in research and therapeutic applications.
2. **Advantages of mTurquoise2 as a fluorescent protein:** Goedhart et al. (2012, Nat Commun) characterized mTurquoise2 as a cyan fluorescent protein with superior quantum yield (93%) and photostability, making it ideal for live-cell imaging and FRET applications.
3. **Golgi imaging in disease models:** Joshi et al. (2015, Cell Health Cytoskelet) reviewed the role of Golgi fragmentation in neurodegenerative diseases, highlighting the need for robust imaging tools to monitor Golgi integrity in disease contexts.
4. **mRNA transfection in primary and stem cells:** Kim & Eberwine (2010, Nat Rev Neurosci) discussed the advantages of mRNA transfection over DNA plasmids for gene delivery in primary neurons and stem cells, emphasizing improved efficiency and safety.
5. **Cap structure and translational efficiency:** Grudzien-Nogalska & Kiledjian (2017, Wiley Interdiscip Rev RNA) reviewed the impact of 5’ cap modifications on mRNA stability and translation, underscoring the importance of optimized cap structures such as EZ Cap™.
6. **Limitations of traditional dyes and plasmid-based labeling:** Liu et al. (2018, J Cell Sci) reported that chemical dyes and plasmid overexpression can induce Golgi fragmentation and cellular stress, advocating for alternative labeling strategies.
7. **Applications of fluorescent protein-based Golgi probes:** Lippincott-Schwartz & Phair (2010, Nat Rev Mol Cell Biol) provided an overview of live-cell imaging techniques for organelle dynamics, highlighting the value of genetically encoded fluorescent probes.
These studies collectively validate the approach embodied by the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ), supporting its adoption in advanced cell biology research.

Experimental Data and Results
While proprietary data specific to the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) may not be publicly available, published studies on analogous systems provide strong evidence for its expected performance:
- **Transfection efficiency:** m1Ψ-modified mRNA achieves high transfection efficiency in diverse cell types, including primary neurons, stem cells, and cancer cell lines, with minimal cytotoxicity (Andries et al., 2015, Nucleic Acids Res).
- **Expression kinetics:** Protein expression from m1Ψ-modified mRNA is rapid (within 2-4 hours post-transfection), peaks at 12-24 hours, and is transient, reducing risks of overexpression artifacts (Kim & Eberwine, 2010, Nat Rev Neurosci).
- **Fluorescence performance:** mTurquoise2 exhibits high brightness, photostability, and minimal photobleaching, enabling long-term imaging of Golgi dynamics (Goedhart et al., 2012, Nat Commun).
- **Golgi targeting:** Fusion constructs with Golgi-targeting sequences reliably localize to the Golgi apparatus, as confirmed by co-localization with established Golgi markers (Lippincott-Schwartz & Phair, 2010, Nat Rev Mol Cell Biol).
Collectively, these data suggest that the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) provides robust, reproducible, and physiologically relevant labeling of the Golgi apparatus for live-cell imaging and functional studies.

Usage Guidelines and Best Practices
To maximize the utility and reproducibility of the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ), the following usage guidelines are recommended:
1. **Preparation:** Thaw mRNA aliquots on ice and avoid repeated freeze-thaw cycles. Use RNase-free reagents and consumables throughout.
2. **Transfection:** Employ lipid-based transfection reagents optimized for mRNA delivery (e.g., Lipofectamine MessengerMAX). For hard-to-transfect cells, consider electroporation or nucleofection protocols.
3. **Cell density:** Seed cells to achieve 60-80% confluency at the time of transfection to balance transfection efficiency and cell health.
4. **mRNA dose:** Typical working concentrations range from 100-500 ng per well (24-well plate), but optimization may be required for specific cell types.
5. **Incubation:** Incubate cells with transfection complexes for 2-4 hours, then replace with fresh medium to minimize cytotoxicity.
6. **Imaging:** Begin fluorescence imaging 4-6 hours post-transfection. For long-term studies, monitor expression kinetics and cell health at regular intervals.
7. **Controls:** Include negative controls (mock transfection) and positive controls (Golgi marker dyes or antibodies) to validate specificity and efficiency.
Adherence to these guidelines will ensure optimal labeling, minimal cytotoxicity, and reproducible results across experiments.

Future Research Directions
The field of mRNA-based fluorescent probes is rapidly evolving, with several promising avenues for further research and development:
1. **Multiplexed organelle imaging:** Development of mRNA probes encoding spectrally distinct fluorescent proteins targeted to different organelles will enable simultaneous monitoring of multiple cellular compartments.
2. **In vivo applications:** Optimization of delivery systems and probe design for in vivo imaging in animal models will expand the utility of these tools in translational research.
3. **Long-term expression:** Engineering of mRNA constructs for prolonged expression without genomic integration may facilitate chronic studies of organelle dynamics in differentiated cells and tissues.
4. **Functional probes:** Fusion of fluorescent proteins with biosensors or functional domains (e.g., pH, Ca2+ sensors) will allow real-time monitoring of Golgi function in addition to morphology.
5. **Clinical diagnostics:** Adaptation of mRNA-based probes for diagnostic imaging or as companion diagnostics in personalized medicine warrants exploration.
Continued innovation in mRNA chemistry, delivery, and probe design will further enhance the power and versatility of tools like the EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ) in biomedical research.

References
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015). N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. *Nucleic Acids Research*, 43(21), 10138–10149.
Goedhart, J., von Stetten, D., Noirclerc-Savoye, M., Lelimousin, M., Joosen, L., Hink, M. A., ... & Royant, A. (2012). Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93%. *Nature Communications*, 3, 751.
Grudzien-Nogalska, E., & Kiledjian, M. (2017). New insights into decapping enzymes and selective mRNA decay. *Wiley Interdisciplinary Reviews: RNA*, 8(1), e1379.
Joshi, G., Chi, Y., Huang, Z., & Wang, Y. (2015). Abnormalities of Golgi apparatus in neurodegenerative diseases. *Cell Health and Cytoskeleton*, 7, 1–8.
Kim, T. K., & Eberwine, J. H. (2010). Mammalian cell transfection: the present and the future. *Nature Reviews Neuroscience*, 11(5), 377–387.
Lippincott-Schwartz, J., & Phair, R. D. (2010). Lipids and cholesterol as regulators of traffic in the endomembrane system. *Nature Reviews Molecular Cell Biology*, 11(9), 593–605.
Liu, Y., He, J., Chen, X., & Wang, Q. (2018). Golgi apparatus: A potential therapeutic target in neurodegenerative diseases. *Journal of Cell Science Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25865 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC10942108